CompletedNot Applicable

Graded TTCE for Post-Embolization PAVM Monitoring

United States32 participantsStarted 2016-10

Plain-language summary

Current HHT guidelines recommend CT scan to detect new or recurrent PAVMs after embolotherapy. Recent studies using transthoracic contrast echocardiography (TTCE) shunt grade for PAVM screening suggest that graded TTCE can accurately predict the size of PAVMs on chest CT and their amenability to embolization. This study's purpose is to evaluate whether TTCE shunt grade can also accurately predict PAVM size and amenability to treatment in patients who are post-embolization.

Who can participate

Age range

18 Years – 89 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age range 18-89 years old * Diagnosis of Hereditary Hemorrhagic Telangiectasia by the Curacao criteria * Prior diagnosis of one or more PAVMs treated by embolotherapy * Chest CT performed within the Penn system for surveillance of PAVMs after \\ embolotherapy Exclusion Criteria: * Known PAVM recurrence on most recent chest CT with feeding artery size amenable to repeat embolotherapy * Known history of intracardiac shunt * Discovery of intracardiac shunt during transthoracic contrast echocardiography

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Differences between TTCE shunt grade and the number of PAVMs present on most recent chest CT scan.

Timeframe: At the time of the echocardiogram (TTCE)

Differences between TTCE shunt grade and the size of PAVMs present on most recent

Timeframe: At the time of the echocardiogram (TTCE)

Trial details

NCT IDNCT02936349

SponsorUniversity of Pennsylvania

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-11

View on ClinicalTrials.gov More Hereditary Hemorrhagic Telangiectasia (HHT) trials